Glenmark US Arm to Launch Sodium Bicarbonate Injection for Metabolic Acidosis

Glenmark Pharmaceuticals announced that its United States-based subsidiary will launch the 8.4% Sodium Bicarbonate Injection USP. This injection is medically recommended for controlling metabolic acidosis, a condition characterized by the body producing excess acid, which can stem from issues like severe kidney disease, uncontrolled diabetes, shock, or high lactic acid levels.

The product, available in a 50 mEq/50 mL single-dose vial, is stated to be bioequivalent and therapeutically equivalent to the reference drug from Abbott Laboratories. Glenmark Pharmaceuticals plans to commence distribution of this injection in November 2025.

According to IQVIA data, the market for this specific 8.4% Sodium Bicarbonate Injection achieved annual sales of roughly $63.8 million over the 12 months concluding in August 2025. Marc Kikuchi, President and Business Head, North America, Glenmark Pharmaceuticals Inc., USA, expressed pleasure in expanding the injectable portfolio with this launch, emphasizing the company's commitment to providing quality, affordable alternatives. Glenmark's product will be marketed strictly for its approved indications.

Impact: This news is likely to have a positive impact on Glenmark Pharmaceuticals' revenue streams from its US operations. The successful launch and market penetration of this generic injection could contribute to the company's overall financial performance, potentially boosting its stock value. For the Indian stock market, the impact will be reflected in Glenmark's share price movement, influenced by investor reaction to its US subsidiary's growth and profitability. Impact Rating: 5/10

Difficult Terms: * **Metabolic Acidosis**: A condition where the body has too much acid or the kidneys cannot remove enough acid. * **Bioequivalent**: Two drugs are bioequivalent if they have the same active ingredient, dosage form, and strength, and their rate and extent of absorption are similar. This means they work in the same way and have the same effect. * **Therapeutically Equivalent**: Drugs that are bioequivalent are also considered therapeutically equivalent. This means they are expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.